Philadelphia—Women with osteoporosis should be treated with bisphosphonates such as alendronate, risedronate, or zoledronic acid or with denosumab, a biologic agent, according to new evidence-based guidelines from the American College of Physicians (ACP). The guidance was published recently in Annals of Internal Medicine and also endorsed by the American Academy of Family Physicians. The expert panel suggests drug therapy for 5 years, noting that continuing treatment after the initial period could be beneficial for some patients and appropriate after reassessing the risks and benefits of continuing therapy. The ACP advises against bone density monitoring during the 5-year period, however, because the evidence does not show any benefit for that. The group also recommends against using menopausal estrogen therapy or menopausal estrogen plus progestin therapy or raloxifene for the treatment of osteoporosis in women because of the risk of serious harms.